Form 4/A for LXEO Lexeo Therapeutics, Inc.
Accepted 2025-09-10 00:00:00 ET · period of report 2025-08-18 · accession 0001415889-25-024104 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2025-09-10 | 2025-08-18 | LXEO | Townsend Richard Nolan | CEO, Dir | S - Sale | $4.67 | -1,115 | 220.1K | -0.5% | -$5,207 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-18 | S | D | 1,115 | $4.67 | 220,058 | D | — | — | (F2) On August 20, 2025, the reporting person filed a Form 4 which inadvertently reported the disposition of 2,735 securities. In fact, as reported in this amendment, the reporting person disposed of 1,115 shares of Common Stock on August 18, 2025. (F3) Includes 131,092 Restricted Stock Units. |